About: Tensions between research and public health: modelling the risks and benefits of SARS-CoV-2 vaccine field trials versus human infection challenge studies.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tensions between research and public health: modelling the risks and benefits of SARS-CoV-2 vaccine field trials versus human infection challenge studies. Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Tensions between research and public health: modelling the risks and benefits of SARS-CoV-2 vaccine field trials versus human infection challenge studies.
Creator	Selgelid, Michael Jamrozik, Euzebiusz Heriot, George
Source	MedRxiv
abstract	Background: Human infection challenge studies (HICS) with SARS-CoV-2 are under consideration as a way of accelerating vaccine development. We evaluate potential vaccine research strategies under a range of epidemic conditions determined, in part, by the intensity of public health interventions. Methods: We constructed a compartmental epidemiological model incorporating public health interventions, vaccine efficacy trials and a post-trial population vaccination campaign. The model was used to estimate the duration and benefits of large-scale field trials in comparison with HICS accompanied by an expanded safety trial, and to assess the marginal risk faced by HICS participants. Results: Field trials may demonstrate vaccine efficacy more rapidly than a HICS strategy under epidemic conditions consistent with moderate mitigation policies. A HICS strategy is the only feasible option for testing vaccine efficacy under epidemic suppression, and maximises the benefits of post-trial vaccination. Less successful or absent mitigation results in minimal or no benefit from post-trial vaccination, irrespective of trial design. Conclusions: SARS-CoV-2 HICS are the optimal method of vaccine testing for populations maintained under epidemic suppression, where vaccination offers the greatest benefits to the local population.
has issue date	2020-05-26(xsd:dateTime)
bibo:doi	10.1101/2020.05.18.20106187
has license	medrxiv
sha1sum (hex)	967383f6546e9e31fd5234f20be0709319e0ef90
schema:url	https://doi.org/10.1101/2020.05.18.20106187
resource representing a document's title	Tensions between research and public health: modelling the risks and benefits of SARS-CoV-2 vaccine field trials versus human infection challenge studies.
resource representing a document's body	covid:967383f6546e9e31fd5234f20be0709319e0ef90#body_text
is schema:about of	named entity 'moderate' named entity 'risk' named entity 'SARS-CoV-2' named entity 'SUCCESSFUL' named entity 'CONCLUSIONS' named entity 'POPULATION' named entity 'accompanied' named entity 'local' named entity 'minimal' named entity 'vaccination' named entity 'epidemic' named entity 'potential' named entity 'vaccination' named entity 'faced' named entity 'assess' named entity 'marginal' named entity 'conditions' named entity 'efficacy' named entity 'expanded' named entity 'Methods' named entity 'trial design' named entity 'vaccine efficacy' named entity 'public health interventions' named entity 'public health interventions' named entity 'vaccination' named entity 'public health' named entity 'SARS-CoV-2' named entity 'vaccination' named entity 'IFR' named entity 'field trial' named entity 'infection' named entity 'selection bias' named entity 'type 1 error' named entity 'infection' named entity 'vaccine' named entity 'vaccine research' named entity 'preprint' named entity 'WHO' named entity '28 days' named entity 'vaccine' named entity 'vaccine efficacy' named entity 'peer review' named entity 'reproductive number' named entity 'epidemic' named entity 'vaccine efficacy' named entity 'vaccine' named entity 'infection' named entity 'preprint' named entity 'excess mortality' named entity 'coronavirus disease 2019' named entity 'critical care' named entity '1.02' named entity 'vaccination campaign' named entity 'vaccine' named entity 'vaccine' named entity 'long-term' named entity '1.02' named entity 'public health' named entity 'medRxiv' named entity 'medRxiv' named entity 'mortality rate' named entity 'mortality rate' named entity 'vaccine' named entity 'infection' named entity 'epidemic' named entity 'medRxiv' named entity 'New York City' named entity 'medRxiv' named entity 'preprint' named entity '1.6' named entity 'general population' named entity 'randomised controlled trials' named entity 'medRxiv' named entity 'vaccine efficacy' named entity 'IFR' named entity 'vaccine' named entity 'infection' named entity 'preprint' named entity 'infection' named entity 'vaccination' named entity 'mass vaccination' named entity 'vaccine' named entity '28 days'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software